Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) EBIT (2016 - 2025)

Standard Biotools (LAB) has disclosed EBIT for 16 consecutive years, with -$32.9 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT fell 23.37% to -$32.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$159.4 million, a 0.41% change, with the full-year FY2024 number at -$175.2 million, down 128.77% from a year prior.
  • EBIT was -$32.9 million for Q3 2025 at Standard Biotools, down from -$19.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$11.3 million in Q4 2021 to a low of -$73.8 million in Q4 2024.
  • A 5-year average of -$29.3 million and a median of -$21.4 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: tumbled 262.7% in 2024, then soared 61.01% in 2025.
  • Standard Biotools' EBIT stood at -$11.3 million in 2021, then crashed by 87.51% to -$21.1 million in 2022, then fell by 1.3% to -$21.4 million in 2023, then tumbled by 245.24% to -$73.8 million in 2024, then soared by 55.39% to -$32.9 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's EBIT are -$32.9 million (Q3 2025), -$19.7 million (Q2 2025), and -$33.0 million (Q1 2025).